Sanctuary Advisors LLC Invests $3.47 Million in United Therapeutics Co. (NASDAQ:UTHR)

Sanctuary Advisors LLC purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,896 shares of the biotechnology company's stock, valued at approximately $3,471,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. KBC Group NV lifted its position in shares of United Therapeutics by 359.3% during the 4th quarter. KBC Group NV now owns 3,766 shares of the biotechnology company's stock valued at $828,000 after acquiring an additional 2,946 shares during the last quarter. Schroder Investment Management Group boosted its position in shares of United Therapeutics by 5.5% in the 4th quarter. Schroder Investment Management Group now owns 187,853 shares of the biotechnology company's stock valued at $41,307,000 after purchasing an additional 9,848 shares during the period. Caxton Associates LP increased its stake in United Therapeutics by 3,088.1% in the 4th quarter. Caxton Associates LP now owns 30,000 shares of the biotechnology company's stock worth $6,597,000 after purchasing an additional 29,059 shares in the last quarter. First Financial Bankshares Inc acquired a new stake in United Therapeutics during the 4th quarter worth about $1,698,000. Finally, Avidity Partners Management LP purchased a new stake in United Therapeutics during the fourth quarter valued at about $52,158,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 1.7 %

UTHR stock traded down $6.08 during trading hours on Monday, hitting $349.85. The company's stock had a trading volume of 361,652 shares, compared to its average volume of 479,914. The company has a market capitalization of $15.52 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 1.28 and a beta of 0.57. The stock has a 50 day moving average price of $344.06 and a two-hundred day moving average price of $300.23. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics's quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the business earned $5.24 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $326.35, for a total value of $1,174,860.00. Following the transaction, the chief executive officer now owns 130 shares of the company's stock, valued at $42,425.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $326.35, for a total value of $1,174,860.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at $42,425.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04. Following the completion of the transaction, the chief financial officer now directly owns 4,802 shares in the company, valued at approximately $1,722,093.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,644 shares of company stock valued at $35,186,166 over the last 90 days. 12.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

UTHR has been the topic of several analyst reports. Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. UBS Group boosted their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a "buy" rating in a research note on Monday, July 8th. Wells Fargo & Company raised their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 20th. Oppenheimer upped their price target on United Therapeutics from $400.00 to $575.00 and gave the company an "outperform" rating in a research report on Wednesday, August 28th. Finally, LADENBURG THALM/SH SH lowered United Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $357.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.